Sign In
Buy MRK
$113.87
-1.62 (-1.40%)
At Close: Jun 18, 2026
7 Best Dow Jones Stocks to Buy for Conservative Investors
09:12am, Thursday, 21'st Dec 2023
With the Federal Reserve seemingly open to the idea of interest rate cuts next year, the narrative for the best Dow Jones stocks for conservative investors appears overly cautious. Don't get me wrong
US FDA declines to approve Merck's chronic cough drug
06:01pm, Wednesday, 20'th Dec 2023
The U.S. Food and Drug Administration (FDA) has declined to approve Merck's drug for chronic cough, the company said on Wednesday, marking the second rejection in less than two years.
Election noise may make pharmaceutical stocks 'untenable' for investors, says Mizuho's Jared Holz
02:50pm, Wednesday, 20'th Dec 2023
Jared Holz, Mizuho healthcare sector specialist, joins 'The Exchange' to discuss the 2024 outlook for health care, which stocks to buy in the new year, and more.
Consider These 3 SWAN Stocks To Collect Dividends Almost Monthly
11:00am, Wednesday, 20'th Dec 2023
Consider These 3 SWAN Stocks To Collect Dividends Almost Monthly
Merck (MRK) Gets EU Nod for Expanded Use in Gastric Cancer
12:02pm, Tuesday, 19'th Dec 2023
Following these approvals, Merck's (MRK) Keytruda is approved for seven gastrointestinal cancers in the European Union. Overall, the drug is approved for 26 indications in the region.
FDA Expands Merck's (MRK) Welireg Label in Renal Cell Carcinoma
02:17pm, Friday, 15'th Dec 2023
Per Merck (MRK), the latest FDA approval to Welireg marks the first time a new treatment has been approved in a novel therapeutic class in advanced renal cell carcinoma since 2015.
Merck (MRK) Stock Declines While Market Improves: Some Information for Investors
06:47pm, Thursday, 14'th Dec 2023
Merck (MRK) concluded the recent trading session at $105.88, signifying a -1.15% move from its prior day's close.
US FDA approves Merck's drug for kidney cancer
05:51pm, Thursday, 14'th Dec 2023
The U.S. Food and Drug Administration on Thursday approved Merck's drug belzutifan for a type of kidney cancer.
MRNA Stock Surges as Moderna Teams Up With Merck to Fight Cancer
04:30pm, Thursday, 14'th Dec 2023
Moderna (NASDAQ: MRNA ) has been on a rough trajectory in recent days. Indeed, continuous declines in MRNA stock earlier this week have hurt investor sentiment in the large-cap biotechnology company.
Moderna-Merck Vaccine for Skin Cancer Shows Positive Results; Moderna Stock Jumps
01:55pm, Thursday, 14'th Dec 2023
A personalized vaccine developed by Moderna (MRNA) and Merck (MRK) showed significant positive results in treating skin cancer in high risk patients.
Moderna's stock rallies 7.9% after announcing positive data in trial of melanoma treatment combined with Merck's Keytruda
06:48am, Thursday, 14'th Dec 2023
Moderna Inc.'s stock MRNA, +0.72% soared 7% early Thursday, after the biotech and partner Merck MRK, +2.65% announced positive data from a mid-stage trial of Moderna's mRNA-4157 in combination with Me
Moderna, Merck vaccine with Keytruda delays return of deadly skin cancer after 3 years, data says
06:30am, Thursday, 14'th Dec 2023
Those results build on midstage trial data Moderna and Merck released earlier this year, which examined the efficacy of the combination over a shorter period.
What Are The Best Stocks To Invest In Now? 2 Health Care Stocks To Watch
11:29am, Wednesday, 13'th Dec 2023
Health care stocks to check out in the stock market now.
C4 Therapeutics stock soars on Merck partnership, license deal
10:41am, Tuesday, 12'th Dec 2023
C4 Therapeutics Inc shares surged 93% to $2.28 in early trading on Tuesday after the clinical-stage biopharmaceutical company announced an exclusive license and collaboration agreement with Merck to d
Merck's (MRK) Keytruda, Lenvima Endometrial Cancer Study Fails
01:32pm, Monday, 11'th Dec 2023
The combination of Merck's (MRK) Keytruda and Eisai's Lenvima for the first-line treatment of advanced/recurrent endometrial carcinoma fails to meet dual primary endpoints in late-stage study.
